Affinia Therapeutics’ was founded in 2019 by Aaron Tward, Botond Roska, Luk Vandenberghe, Rob Aboud, and Robert Johnson. Affina Therapeutics has made an S-1 public filing.
Affinia Therapeutics’ purpose is to develop gene therapies that can have a transformative impact on people affected by devastating rare and non-rare diseases and methodically engineer novel AAV vectors and regulatory elements to make gene therapies with potentially improved tissue tropism, cell specificity, safety, and yields. Per Forge data, Affinia Therapeutics has raised a total of $170 million in funding over 2 rounds. Their latest funding was raised on May 3, 2021, from a Series B round. Key investors include Farallon Capital Management, F-Prime Capital, New Enterprise Associates, and EcoR1 Capital.
These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
05/03/2021 | Series B | $110MM | $xx.xx | $365.7MM | Atlas Venture, Avidity Partners, Casdin Capital, Ecor1 Capital, Farallon Capital Management, F-Prime Capital, Gv, Lonza, Mass General Brigham Ventures, New Enterprise Associates, Octagon Capital, Perceptive Advisors, Ra Capital Management, Tcg Crossover, Woodline Partners Lp | |
Price per Share
$xx.xx
Shares Outstanding
20,813,930
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Atlas Venture, Avidity Partners, Casdin Capital, Ecor1 Capital, Farallon Capital Management, F-Prime Capital, Gv, Lonza, Mass General Brigham Ventures, New Enterprise Associates, Octagon Capital, Perceptive Advisors, Ra Capital Management, Tcg Crossover, Woodline Partners Lp
|
||||||
03/31/2020 | Series A | $60.57MM | $xx.xx | $116.71MM | Alexandria Venture Investments, Atlas Venture, F-Prime Capital, Lonza, New Enterprise Associates, Partners Innovation Fund | |
Price per Share
$xx.xx
Shares Outstanding
23,736,223
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Atlas Venture, F-Prime Capital, Lonza, New Enterprise Associates, Partners Innovation Fund
|
||||||
11/05/2019 | Series A-1 | $8.52MM | $xx.xx | $42.61MM | Alexandria Venture Investments, F-Prime Capital, Lonza, New Enterprise Associates, Partners Innovation Fund | |
Price per Share
$xx.xx
Shares Outstanding
3,706,187
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, F-Prime Capital, Lonza, New Enterprise Associates, Partners Innovation Fund
|